Pipemidic acid, a new treatment for recurrent urinary tract infection in small animals

Abstract

A new chemotherapeutic agent, pipemidic acid, was used to treat 14 dogs and 2 cats with recurrent urinary tract infection caused by multiresistent strains of Escherichia coli and Proteus spp. Bacterial culture of the urine after treatment revealed disappearance of the microorganisms in all patients. It is concluded that pipemidic acid is a promising chemotherapeutic agent for urinary tract infections caused by multiresistant E. coli and Proteus spp., with the condition that bacterial culture during the course of treatment is obligatory.

From pipemidic acid molecular salts to metal complexes and BioMOFs using mechanochemistry

“…3 Herein we present results using pipemidic acid (PA) (Fig. 1), a first-generation quinolone antibiotic used to treat urinary tract infections owing to its antibacterial activity against both Gram-negative 23 and Gram-positive bacteria. 24,25 Quinolone antibiotics are broad-spectrum synthetic antibacterial compounds presenting suitable oral absorption and bioavailability, 26,27 results on their antitumor, anticancer and antiviral activities have also been reported.…”

Bioactivity of Isostructural Hydrogen Bonding Frameworks Built from Pipemidic Acid Metal Complexes

“…This addition increased the lipophilicity of the compound, which has subsequently increased its ability to penetrate the bacterial cell wall [8,14]. Pipemidic acid is mostly used as a therapeutic agent to treat urinary tract infections due to its antibacterial activity against Gram-negative [15] and some Gram-positive bacteria [16,17].…”

“…This addition increased the lipophilicity of the compound, which has subsequently increased its ability to penetrate the bacterial cell wall [8,14]. Pipemidic acid is mostly used as a therapeutic agent to treat urinary tract infections due to its antibacterial activity against Gram-negative [15] and some Gram-positive bacteria [16,17]. However, this family of compounds has become ineffective at treating certain bacterial infections, despite the efforts to induce modifications to the typical quinolone structure once bacteria have been shown to rapidly adapt and develop resistance [6,9].…”